Therma Bright Sells an Additional 200-Units of Venowave(TM) to Strategic Distribution Partner Gen-X Med

Executive Summary

• Therma Bright Inc. received a follow‑on order for an additional 200 Venowave™ VW5 units from its Texas distributor, Gen‑X Med.
• The order expands the existing partnership and reflects strong clinical demand for the portable compression therapy device in the U.S. orthopedic market.
• Management highlights the growth potential of the compression therapy market, which is projected to reach $6.72 billion by 2033 (CAGR 7.30%).

Key Details

• Order Size: 200 Venowave™ VW5 units – follow‑on to an initial rollout with Gen‑X Med.
• Customer: Gen‑X Med, Arlington, Texas – a specialized healthcare distributor serving orthopedic surgeons.
• Product Description: Venowave™ VW5 is a battery‑operated peristaltic pump (portable DME) approved for Medicare reimbursement (HCPCS E0683). Clinically shown to increase venous blood flow by 64% after 2 min and 88% after 50 min.
• Market Context: Global compression therapy market valued at $4.18 billion in 2024, projected to reach $6.72 billion by 2033 (CAGR 7.30%). Growth driven by aging population, rising orthopedic surgeries, and DVT prevention focus.
• Strategic Implication: The repeat order underscores market acceptance of Venowave™ VW5 and supports Therma Bright’s growth strategy in the high‑growth U.S. post‑surgical recovery segment.

Notable Quotes

“The speed at which Gen‑X Med has returned for additional inventory speaks volumes about the clinical demand for the Venowave™ VW5… We look forward to scaling this volume as Gen‑X Med continues to educate their expansive doctor network.” – Rob Fia, CEO

“Securing these additional 200 units allows us to keep pace with the growing adoption rate among our specialized knee surgeons… Venowave™ is the clear leader in that transition.” – Beau Wood, President, Gen‑X Med